OTC:ZOMDF Zomedica (ZOMDF) Stock Price, News & Analysis $0.04 0.00 (-1.71%) As of 03:01 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Zomedica Stock (OTC:ZOMDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zomedica alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.02▼$0.16Volume1.22 million shsAverage Volume3.91 million shsMarket Capitalization$39.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Read More Zomedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreZOMDF MarketRank™: Zomedica scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Zomedica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Zomedica is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zomedica is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Zomedica has been sold short.Short Interest Ratio / Days to CoverZomedica has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zomedica has recently decreased by 15.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZomedica does not currently pay a dividend.Dividend GrowthZomedica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the float of Zomedica has been sold short.Short Interest Ratio / Days to CoverZomedica has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zomedica has recently decreased by 15.99%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News SentimentN/A News SentimentZomedica has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zomedica this week, compared to 0 articles on an average week.Search Interest2 people have searched for ZOMDF on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Zomedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zomedica insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.58% of the stock of Zomedica is held by insiders.Percentage Held by InstitutionsOnly 8.95% of the stock of Zomedica is held by institutions.Read more about Zomedica's insider trading history. Receive ZOMDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address ZOMDF Stock News HeadlinesZomedica Corp. Reports Q2 2025 Financial ResultsAugust 22, 2025 | msn.comZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | financialpost.comF“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)Zomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | globenewswire.comZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comZomedica Corp. (ZOMDF)April 12, 2025 | finance.yahoo.comSee More Headlines ZOMDF Stock Analysis - Frequently Asked Questions How have ZOMDF shares performed this year? Zomedica's stock was trading at $0.1229 at the start of the year. Since then, ZOMDF shares have decreased by 66.0% and is now trading at $0.0418. How do I buy shares of Zomedica? Shares of ZOMDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTC SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTC:ZOMDF Previous SymbolOTC:ZOMDF CIK1684144 Webwww.zomedica.com Phone734 369 2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free FloatN/AMarket Cap$40.96 million OptionableN/A Beta1.60 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTC:ZOMDF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.